Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of VV261 in Healthy Participants
NCT07710326Phase 1Not yet recruiting
- Sponsor
- Vigonvita Life Sciences
- Start
- Aug 2026
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing VV261 with Placebo (2 arms). Primary endpoints: Maximum Observed Plasma Concentration, Time to Maximum Plasma Concentration and 8 more. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
4'-fluorouridine
Beyond the preview
Go deeper on NCT07710326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07710326.